DrugCite
Search

AZULFIDINE EN TABS

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Azulfidine En Tabs Adverse Events Reported to the FDA Over Time

How are Azulfidine En Tabs adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Azulfidine En Tabs, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Azulfidine En Tabs is flagged as the suspect drug causing the adverse event.

Most Common Azulfidine En Tabs Adverse Events Reported to the FDA

What are the most common Azulfidine En Tabs adverse events reported to the FDA?

Pyrexia
50 (4.76%)
Interstitial Lung Disease
30 (2.85%)
Rash
30 (2.85%)
Liver Disorder
28 (2.66%)
Pneumonia
27 (2.57%)
Hepatic Function Abnormal
23 (2.19%)
Pancytopenia
19 (1.81%)
Agranulocytosis
17 (1.62%)
Malaise
17 (1.62%)
Platelet Count Decreased
16 (1.52%)
Erythema
15 (1.43%)
Show More Show More
Arthralgia
11 (1.05%)
Condition Aggravated
11 (1.05%)
Drug Eruption
11 (1.05%)
Glomerulonephritis Membranous
11 (1.05%)
Sepsis
11 (1.05%)
Drug Rash With Eosinophilia And Sys...
10 (.95%)
Vomiting
10 (.95%)
White Blood Cell Count Decreased
10 (.95%)
Nausea
9 (.86%)
Neutropenia
9 (.86%)
Anorexia
8 (.76%)
Diarrhoea
8 (.76%)
Dizziness
8 (.76%)
Drug Hypersensitivity
8 (.76%)
Dyspnoea
8 (.76%)
Eczema
8 (.76%)
Hypersensitivity
8 (.76%)
Shock
8 (.76%)
Alanine Aminotransferase Increased
7 (.67%)
Generalised Erythema
7 (.67%)
Iga Nephropathy
7 (.67%)
Leukopenia
7 (.67%)
Lymphadenopathy
7 (.67%)
Nasopharyngitis
7 (.67%)
Nephrotic Syndrome
7 (.67%)
Rash Generalised
7 (.67%)
Thrombocytopenia
7 (.67%)
Toxic Skin Eruption
7 (.67%)
Cough
6 (.57%)
Fatigue
6 (.57%)
Headache
6 (.57%)
Infectious Mononucleosis
6 (.57%)
Tachycardia
6 (.57%)
Bone Marrow Failure
5 (.48%)
Drug Ineffective
5 (.48%)
Gastrointestinal Perforation
5 (.48%)
Hypertension
5 (.48%)
Petechiae
5 (.48%)
Pruritus
5 (.48%)
Respiratory Failure
5 (.48%)
Abdominal Pain
4 (.38%)
Acute Lymphocytic Leukaemia
4 (.38%)
C-reactive Protein Increased
4 (.38%)
Chills
4 (.38%)
Conjunctivitis
4 (.38%)
Decreased Appetite
4 (.38%)
Face Oedema
4 (.38%)
Haemoptysis
4 (.38%)
Infection
4 (.38%)
Large Intestine Perforation
4 (.38%)
Melaena
4 (.38%)
Neutrophil Count Decreased
4 (.38%)
Oedema Peripheral
4 (.38%)
Peritonitis
4 (.38%)
Pulmonary Fibrosis
4 (.38%)
Rheumatoid Arthritis
4 (.38%)
Stevens-johnson Syndrome
4 (.38%)
Toxic Epidermal Necrolysis
4 (.38%)
White Blood Cell Count Increased
4 (.38%)
Abdominal Mass
3 (.29%)
Aplastic Anaemia
3 (.29%)
Aspartate Aminotransferase Increase...
3 (.29%)
Asthenia
3 (.29%)
Biliary Tract Disorder
3 (.29%)
Blood Alkaline Phosphatase Increase...
3 (.29%)
Blood Bilirubin Increased
3 (.29%)
Blood Pressure Decreased
3 (.29%)
Blood Pressure Systolic Increased
3 (.29%)
Brain Abscess
3 (.29%)
Cardiac Disorder
3 (.29%)
Cellulitis
3 (.29%)
Constipation
3 (.29%)
Decreased Interest
3 (.29%)
Depressed Level Of Consciousness
3 (.29%)
Dermatitis Psoriasiform
3 (.29%)
Eosinophilia
3 (.29%)
Feeling Abnormal
3 (.29%)
General Physical Health Deteriorati...
3 (.29%)
Granulocytopenia
3 (.29%)
Haemoglobin Decreased
3 (.29%)
Hepatitis Acute
3 (.29%)
Hypervigilance
3 (.29%)
Leukoencephalopathy
3 (.29%)
Liver Function Test Abnormal
3 (.29%)
Measles
3 (.29%)
Mycobacterium Avium Complex Infecti...
3 (.29%)
Oculomucocutaneous Syndrome
3 (.29%)
Peptic Ulcer
3 (.29%)
Pneumocystis Jiroveci Pneumonia
3 (.29%)
Pruritus Generalised
3 (.29%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Azulfidine En Tabs, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Azulfidine En Tabs is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Azulfidine En Tabs

What are the most common Azulfidine En Tabs adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Azulfidine En Tabs, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Azulfidine En Tabs is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Azulfidine En Tabs According to Those Reporting Adverse Events

Why are people taking Azulfidine En Tabs, according to those reporting adverse events to the FDA?

Rheumatoid Arthritis
408
Musculoskeletal Pain
20
Crohns Disease
15
Drug Use For Unknown Indication
14
Arthralgia
7
Colitis Ulcerative
5
Show More Show More
Ankylosing Spondylitis
4
Juvenile Arthritis
3
Caplans Syndrome
3
Ill-defined Disorder
3
Exostosis
3
Sapho Syndrome
2
Arrhythmia
2
Uveitis
2
Psoriatic Arthropathy
2
Rosacea
1
Fatigue
1
Neoplasm
1
Joint Swelling
1
Decreased Interest
1
Irritable Bowel Syndrome
1

Drug Labels

LabelLabelerEffective
Azulfidine En-tabsPharmacia and Upjohn Company LLC03-DEC-12

Azulfidine En Tabs Case Reports

What Azulfidine En Tabs safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Azulfidine En Tabs. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Azulfidine En Tabs.